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Previewsthe interplay of inputs that regulate CAD
and how their dysregulation may con-
tribute to altered pyrimidine biosynthesis
and cancer.
Another open question is why mTORC1
appears to have more direct control over
the synthesis of pyrimidines than that of
purines. Under the same conditions in
which Robitaille et al. observed a serum-
induced, rapamycin-inhibited increase in
UTP, they saw no rapamycin-dependent
changes in GTP or GDP levels. Synthesis
of both purines and pyrimidines requires
the synthesis of the nitrogenous base and
ribose, derived from the pentose phos-
phate pathway (Figure 1). mTORC1
transcriptionally activates the pentose
phosphate pathway (Du¨vel, et al., 2010),
so mTORC1 can indirectly contribute to
the biosynthesis of both types of nucleo-
tide. However, Ben-Sahra et al. foundthat extended rapamycin treatment was
required to see decreased ribose produc-
tion as compared to the rapid decrease in
pyrimidine production. Thus, in agreement
with Robitaille et al., it appears that
mTORC1 has tighter control over the
synthesis of pyrimidines than purines.
Further work should determine if pyrimi-
dine synthesis indeed plays a greater role
in rapidly growing/dividing cells than
purine synthesis, potentially to equilibrate
levels of pyrimidines and purines for
times of increased DNA synthesis or
ribosome biogenesis. Thus, the studies of
Ben-Sahra et al. and Robitaille et al.
demonstrate a novel role for mTORC1-
activated S6K in regulating pyrimidine
synthesis through the direct phosphor-
ylation-dependent regulation of CAD, a
mechanism that may be exploited to halt
growth of cancers.Cell MetabolisREFERENCES
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Whether the red wine component resveratrol directly activates the NAD+-dependent protein deacetylase
SIRT1 has been debated. A recent study by Hubbard et al. (2013) strengthens the case that SIRT1-activating
compounds (STACs) function as positive allosteric regulators of SIRT1 and thereby regulate mitochondrial
function.A small molecule that effectively delays
the onset of aging-associated diseases,
such as neurodegeneration, diabetes,
and cancer, has the potential to revolu-
tionize modern medicine. One candidate
molecule is resveratrol, an antioxidant
present in red wine discovered to be a
naturally occurring SIRT1 activator. Re-
sveratrol extends life span in yeast,
worms, and flies (Wood et al., 2004) and
improves metabolic parameters in aged
mice and obese humans (Baur et al.,
2006; Timmers et al., 2011). Soon after
the seminal report showing that resvera-
trol activates SIRT1, novel synthetic
SIRT1 activators were identified and
further developed to reduce off-target
effects and improve their pharmacoki-netic properties. However, a number of
controversies arose regarding themecha-
nism of action of resveratrol and synthetic
SIRT1-activating compounds (STACs). Of
significant concern was the demon-
stration that STACs and resveratrol
enhanced SIRT1 deacetylase activity
toward peptide substrates covalently
bound to a fluorophore but not toward
native peptide substrates (Pacholec
et al., 2010). This discrepancy raised sig-
nificant questions on the validity of re-
sveratrol and STACs as direct SIRT1
activators in vivo. However, subsequent
studies showed that STAC treatment
offered remarkable protective benefits
against cardiovascular andmetabolic dis-
ease as well as locomotor dysfunction inaged mice, revealing some discrepancy
between the in vitro and in vivo effects
(Baur et al., 2012).
To address this controversy, Sinclair
and his team (who published the original
resveratrol/SIRT1 story [Howitz et al.,
2003]), set out to re-evaluate their previ-
ous findings by testing a clever alternative
hypothesis. Could the failure of STACs to
deacetylate native, nontagged peptides
in vitro be explained by a requirement for
the structure mimicked by the fluorophore
tag? In other words, was the bulky, hydro-
phobic fluorophore mimicking properties
of endogenous substrates required for
SIRT1 activation by STACs? Two inde-
pendent assays, one enzymatic and the
other mass-spectrometry based, werem 17, May 7, 2013 ª2013 Elsevier Inc. 635
Figure 1. Resveratrol and Synthetic STACs Are Allosteric Activators of the Deacetylase
SIRT1
A glutamic acid residue (Glu230) adjacent to the catalytic core of SIRT1 is required, but not sufficient, for the
lowering of KM toward its substrates by STACs. In addition, a hydrophobic motif in proximity to the
acetylated lysine residues of endogenous substrates is necessary. PGC-1a, a key regulator of mitochon-
drial biogenesis, is a target of SIRT1 and its deacetylation is dependent on the presence of hydrophobic
amino acids at positions +1 and +6 with respect to the acetylated lysine. The conditional activation of
SIRT1 by STACs is referred to as ‘‘assisted allosteric activation.’’ Ac = Acetyl; K = Lysine; Y = Tyrosine;
F = Phenylalanine.
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Previewsused to interrogate SIRT1 deacetylation
kinetics. As correctly predicted, they
found that the fluorophore lowered the
Michaelis constant (Km) in response to
STACs only when located directly adja-
cent to the acetylated lysine 9 of histone
3 (H3K9) at the +1 position. Furthermore,
a fluorophore moiety at positions +1 and
+6 could be substituted with naturally
occurring bulky hydrophobic amino acids
such as tryptophan, tyrosine, or phenylal-
anine, and still support SIRT1 activa-636 Cell Metabolism 17, May 7, 2013 ª2013tion by resveratrol. Importantly, STAC-
mediated lowering of the peptide Km
toward two endogenous SIRT1 sub-
strates, peroxisome proliferator-activated
receptor g coactivator 1 a lysine 778
(PGC-1a-K778) and human forkhead
box O3a protein lysine 290 (FOXO3a-
K290), also depended on hydrophobic
amino acids at positions +1 and +6
(PGC1-a) and +1 (FOXO3a). A screen for
a peptide consensus motif incorporating
these amino acids in proximity to a lysineElsevier Inc.revealed 400 matching sequences within
the nuclear proteome. Five of these
peptides were tested and it was found
that their deacetylation by SIRT1 was
enhanced by STACs.
These results suggest an ‘‘assisted
allosteric mechanism,’’ in which STACs
activate SIRT1 only in the context of
unique peptide substrates (Figure 1).
Importantly, a mutagenesis screen further
showed that substitution of glutamic acid
230 (Glu230) of SIRT1 with lysine or
alanine attenuated resveratrol-induced
SIRT1 enzymatic activity, both in fluo-
rophore-tagged and native peptide
sequences. Testing of a panel of 117
STACs confirmed the global requirement
of Glu230 for allosteric activation of
SIRT1 by members of this drug class,
suggesting a shared mechanism. Finally,
to translate these findings into mam-
malian physiology, primary myoblasts
and primary embryonic fibroblasts from
SIRT1 knockout mice were reconstituted
with either wild-type or mutated SIRT1
(SIRT1-E222K, the murine equivalent of
human SIRT1-E230K). Importantly, this
single amino-acid substitution in SIRT1
completely suppressed the effect of
resveratrol in promoting increased mito-
chondrial mass and ATP content. These
experiments support the model that
STACs activate SIRT1 directly and that
some of the biological effects of resvera-
trol and STACs are strictly dependent on
SIRT1 (Figure 1).
Having re-established SIRT1 as an
important target of resveratrol and
STACs, the field can now focus again on
key remaining questions. Are sirtuins valid
and safe targets to extend health and life
span? While controversy has also sur-
rounded the role of sirtuin in aging, recent
work brings renewed support for a role of
sir2 in Drosophila aging (Banerjee et al.,
2012). Moving forward, it will be important
to determine which of the biological
effects of resveratrol are mediated by
SIRT1 and what other cellular targets
mediate its SIRT1-independent effects.
Given its small size (MW = 228 Da), it is
quite likely that resveratrol regulates the
activity of other cellular proteins in addi-
tion to SIRT1. Indeed, resveratrol binds
to a hydrophobic pocket of the F1-
ATPase and inhibits this key enzyme in
mitochondrial respiration (Gledhill et al.,
2007). Resveratrol also inhibits several
phosphodiesterase (PDE) isoforms
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Previewsin vitro and shares several biological
effects with the selective PDE4 inhibitor
rolipram when administered to obese
mice (Park et al., 2012). In this study, re-
sveratrol and rolipram are postulated to
indirectly activate AMP-activated protein
kinase (AMPK) via a cAMP/Epac1/
CamKKb axis. The canonical function of
AMPK is to sense high AMP:ATP ratios
during energetic stress. Several homeo-
static responses, including an increase
in mitochondrial biogenesis through
PGC-1a, are initiated by AMPK signaling
and promote metabolic health. Since
AMPK is activated in conditions when
ATP levels are reduced, this pathway
may also be triggered through inhibition
of F1-ATPase by resveratrol. The variety
of cellular targets for resveratrol may
explain its pleiotropic pharmacological
effects and complicate the analysis of its
effects on the complex trait of aging. The
existence of a SIRT1 allosteric site distinct
from the catalytic pocket also leads to the
exciting hypothesis that endogenousmetabolites or regulatory protein(s) may
target this site. Candidate metabolites
are likely to undergo dynamic changes
during calorie restriction and feeding-
fasting cycles.
The discovery of a pharmacological
equivalent of the fountain of youth still
faces a long and uncertain path ahead.
Nevertheless, the report by Hubbard
et al. (2013) brings renewed focus on the
role of SIRT1 as an important target for
calorie restriction mimetics and opens
new avenues to further explore SIRT1
activation as a means to promote healthy
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